vTv Therapeutics Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes

Reuters

05-20

vTv <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes

vTv Therapeutics Inc. has announced the reinitiation of its CATT1 Phase 3 clinical trial for cadisegliatin, an investigational oral adjunctive therapy to insulin for the treatment of type 1 diabetes. This development follows the company's appointment of Michael Tung, M.D., MBA, as the new Chief Financial Officer. Dr. Tung brings over 20 years of experience in finance and strategic leadership within the biopharmaceutical industry. The trial aims to further explore cadisegliatin's potential as a first-in-class therapy to enhance diabetes management. This initiative represents a key step forward in vTv Therapeutics' efforts to advance its pipeline and achieve its strategic objectives in the field of diabetes treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641489-25-000032), on May 19, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2536063770"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536063770\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2536063770?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536063770","market":"nz","top_or_hot":-1,"title":"vTv Therapeutics Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      vTv <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VTVT\">vTv Therapeutics Inc.</a> has announced the reinitiation of its CATT1 Phase 3 clinical trial for cadisegliatin, an investigational oral adjunctive therapy to insulin for the treatment of type 1 diabetes. This development follows the company's appointment of Michael Tung, M.D., MBA, as the new Chief Financial Officer. Dr. Tung brings over 20 years of experience in finance and strategic leadership within the biopharmaceutical industry. The trial aims to further explore cadisegliatin's potential as a first-in-class therapy to enhance diabetes management. This initiative represents a key step forward in vTv Therapeutics' efforts to advance its pipeline and achieve its strategic objectives in the field of diabetes treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641489-25-000032), on May 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>vTv Therapeutics Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nvTv Therapeutics Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-20 04:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      vTv <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VTVT\">vTv Therapeutics Inc.</a> has announced the reinitiation of its CATT1 Phase 3 clinical trial for cadisegliatin, an investigational oral adjunctive therapy to insulin for the treatment of type 1 diabetes. This development follows the company's appointment of Michael Tung, M.D., MBA, as the new Chief Financial Officer. Dr. Tung brings over 20 years of experience in finance and strategic leadership within the biopharmaceutical industry. The trial aims to further explore cadisegliatin's potential as a first-in-class therapy to enhance diabetes management. This initiative represents a key step forward in vTv Therapeutics' efforts to advance its pipeline and achieve its strategic objectives in the field of diabetes treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641489-25-000032), on May 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL7nzy6K:1","article_id":"2536063770","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536063770","pubTimestamp":1747686303,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"vTv Therapeutics Inc. has announced the reinitiation of its CATT1 Phase 3 clinical trial for cadisegliatin, an investigational oral adjunctive therapy to insulin for the treatment of type 1 diabetes. This development follows the company's appointment of Michael Tung, M.D., MBA, as the new Chief Financial Officer. Dr. Tung brings over 20 years of experience in finance and strategic leadership within the biopharmaceutical industry. The trial aims to further explore cadisegliatin's potential as a first-in-class therapy to enhance diabetes management. This initiative represents a key step forward in vTv Therapeutics' efforts to advance its pipeline and achieve its strategic objectives in the field of diabetes treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VTVT":"vTv Therapeutics Inc."},"translate_title":"vTv Therapeutics重新启动Cadisegliatin的3期试验，这是一种有前途的1型糖尿病口服辅助疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTVT":0.9},"content_text":"vTv Therapeutics Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes\n    \n\nvTv Therapeutics Inc. has announced the reinitiation of its CATT1 Phase 3 clinical trial for cadisegliatin, an investigational oral adjunctive therapy to insulin for the treatment of type 1 diabetes. This development follows the company's appointment of Michael Tung, M.D., MBA, as the new Chief Financial Officer. Dr. Tung brings over 20 years of experience in finance and strategic leadership within the biopharmaceutical industry. The trial aims to further explore cadisegliatin's potential as a first-in-class therapy to enhance diabetes management. This initiative represents a key step forward in vTv Therapeutics' efforts to advance its pipeline and achieve its strategic objectives in the field of diabetes treatment.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641489-25-000032), on May 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}